What did @drmichaelsays actually say?
The creator, going by Dr. Mike, warned viewers to stop buying peptides online without understanding the risks. He focused on a trio called the "Glow Stack" — GHK-Cu, BPC-157, and TB-500 — and framed them as widely used anti-aging and skin health peptides. His core argument was two-part: these peptides have real biological mechanisms worth knowing about, and the biggest risk is that VEGF-driven angiogenesis could theoretically feed an undiagnosed tumor. He also claimed that 60% of peptides sold online do not contain what they claim.
He described GHK-Cu as a "copper shuttle" that activates enzymes to improve collagen crosslinking, said BPC-157 binds to VEGFR2 receptors and triggers nitric oxide-driven blood vessel formation, and described TB-500 as binding to G-actin to promote cell migration and structural repair. The framing was cautionary, which is not nothing in a space full of uncritical promotion.
Does the science back this up?
Partially, but the mechanisms are oversimplified and in some cases outright wrong. GHK-Cu does influence collagen synthesis, but the enzyme-crosslinker explanation is reductive. BPC-157's VEGFR2 binding and nitric oxide pathway has some rodent data behind it, but calling it established human pharmacology overstates the evidence significantly. The tumor risk framing is the most defensible part of this video.
GHK-Cu has been studied for its role in wound healing and skin remodeling. Pickart et al. (2015, Journal of Aging Research) documented its effects on collagen gene expression, though most evidence remains in vitro or animal-based. BPC-157's angiogenic properties are real in rodent models — Sikiric et al. have published extensively on this in journals like Current Pharmaceutical Design — but there are no robust human clinical trials. TB-500's mechanism involves thymosin beta-4 and actin sequestration, which does affect cell motility, but "G-actin binding" is a simplification of a more complex cytoskeletal interaction (Goldstein and Bhatt, 2010, Annals of the New York Academy of Sciences). The VEGF-tumor concern has a legitimate theoretical basis, though no clinical study has demonstrated this outcome specifically from BPC-157 use in humans.
What did they get wrong (or right)?
The tumor warning is the right instinct delivered with imprecise language. The 60% contamination statistic is the most unverifiable claim in the video, and it needed a source. The mechanistic explanations are mixed, ranging from roughly accurate to misleading.
Calling BPC-157's mechanism "nitrogen oxide" instead of nitric oxide is a small but telling slip. Describing GHK-Cu as playing with "vascular DNA" is not a scientific statement; it is rhetorical framing that could mislead viewers into thinking these peptides directly alter their genome, which they do not in any established sense. The VEGF-tumor concern is theoretically grounded. VEGF signaling is a known driver of tumor angiogenesis, and this is the basis for anti-VEGF cancer therapies like bevacizumab. However, presenting this as a near-certainty rather than a theoretical risk in unscreened individuals goes further than the current evidence supports. The 60% figure is frequently cited in online peptide circles but has no published peer-reviewed source this reviewer could locate. Without attribution, it should be treated as unverified. Credit where it is due: warning about lack of medical oversight and online product quality is legitimate public health messaging that most influencers in this space skip entirely.
What should you actually know?
None of these three peptides have completed phase III clinical trials in humans for anti-aging or cosmetic purposes. That is the most important thing this video did not say clearly enough. Everything else follows from that gap.
GHK-Cu has a reasonable safety profile in topical applications and is used in cosmetic formulations. Systemic injectable use is a different question with far less data. BPC-157 is not approved by the FDA or EMA for any indication. It has been removed from some compounding pharmacy approved ingredient lists in the United States. TB-500, or more precisely synthetic thymosin beta-4 fragments, sits in a similar regulatory gray area. Sourcing matters enormously. Independent testing by organizations like Janoshik and others has repeatedly found peptide products sold online to be mislabeled, underdosed, or contaminated with bacterial endotoxins. Anyone considering these compounds should at minimum require a certificate of analysis from an independent third-party lab. A conversation with a physician who actually understands peptide pharmacology, not just one who repeats TikTok talking points, is not optional. It is the baseline.